$LUNG

BlackRock (LUNG) updates Pulmonx Corp stake, reports 765,721 shares owned

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 765,721 shares of Pulmonx Corp common stock, or 1.8% of the class. The filing states BlackRock has sole voting and sole dispositive power over the shares, with no shared power. It also notes underlying clients may receive dividends or sale proceeds.

Original reporting
Published Jul 29, 2026, 7:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 30, 2026, 12:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

The disclosure confirms BlackRock’s sole voting and dispositive control over 765,721 Pulmonx shares, but does not indicate control, activism, or a transaction.

02

Market read

Ownership reporting can slightly influence sentiment around shareholder structure, but this specific filing provides no new fundamental catalyst for Pulmonx.

03

What to watch

Traders may want to check whether the amendment reflects a true increase/decrease versus administrative timing, and whether any other large holders filed contemporaneously.

Relevance 4/10Novelty 4/10Timing: as of the amended Schedule 13G filing date (2026-07-29)

Background

The article summarizes an amended Schedule 13G, which reports beneficial ownership of 5% or less of a class, typically for investment purposes.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

BlackRock amended Schedule 13G to report beneficial ownership of 765,721 Pulmonx shares, or 1.8% of the class.

Expected impact

Low likelihood of a sustained price move solely from this filing; any reaction would likely be small and short-lived.

Evidence & confidence

The filing reports 1.8% ownership with sole voting and dispositive power, but remains below the 5% threshold and contains no accompanying operational, regulatory, or transaction catalyst.

Market effects

No sector-level implications; this is a single-issuer ownership disclosure.

None indicated.

None indicated.

Counterpoint

Because the stake is only 1.8% and below 5%, the market may treat it as routine re-reporting rather than a meaningful new position change.

Key entities

  • BlackRock, Inc.

    Filed an amended Schedule 13G reporting beneficial ownership of Pulmonx Corp common stock.

  • Pulmonx Corp

    The issuer whose common stock ownership is being reported, with BlackRock disclosing 1.8% beneficial ownership.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the secon